Navigation Links
Keryx Biopharmaceuticals to Present at Lazard Capital Markets 7th Annual Healthcare Conference
Date:11/15/2010

NEW YORK, Nov. 15, 2010 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that Ron Bentsur, the Company's Chief Executive Officer, will be presenting at the Lazard Capital Markets 7th Annual Healthcare Conference, being held at the St. Regis Hotel in New York City.  Mr. Bentsur's presentation is scheduled to take place on Wednesday, November 17, 2010, at 10:00 a.m.

A live audio webcast of Mr. Bentsur's presentation will be accessible from the Investor Information page of the Company's Website at http://investors.keryx.com. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT KERYX BIOPHARMACEUTICALS, INC.Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, and also affects a number of other key signal transduction pathways, including the JNK pathway, all of which are pathways associated with programmed cell death, cell growth, cell differentiation and cell survival. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 is currently in Phase 3 clinical development for both refractory advanced colorectal cancer and multiple myeloma, and in Phase 1 and 2 clinical development for several other tumor types. Each of the KRX-0401 Phase 3 programs are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. Keryx is also developing Zerenex(TM) (ferric citrate), an ora
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Keryx Biopharmaceuticals to Present at the UBS 2010 Global Life Sciences Conference
2. Æterna Zentaris Partner Keryx Announces Special Protocol Assessment Agreement with FDA for Phase 3 Trial of Perifosine (KRX-0401) in the Treatment of Patients with Refractory Metastatic Colorectal Cancer
3. Æterna Zentaris Partner Keryx Announces Positive Phase 2 Results for Perifosine as a Single Agent for the Treatment of Advanced Waldenstroms Macroglobulinemia
4. Æterna Zentaris Partner Keryx Reports a Statistically Significant Benefit in Survival from Updated Results of a Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Perifosine (KRX-0401) in the Treatment of Advanced Metastatic Colon Cancer
5. AEterna Zentaris Partner, Keryx, Initiates Phase 3 Registration Trial with Perifosine (KRX-0401) for the Treatment of Patients with Advanced Multiple Myeloma
6. AEterna Zentaris Partner, Keryx, Reports Updated Phase 1/2 Data, Including New Survival Data, on Perifosine (KRX-0401) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
7. AEterna Zentaris Partner, Keryx Biopharmaceuticals, Receives Orphan-Drug Designation for Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
8. Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT
10. AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma
11. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... September 22, 2014 Research ... addition of the "Global Biotechnology Reagents Market ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) Biotechnology reagents are ... a system to detect and examine another substance ... used in laboratories to prepare, collect, and examine ...
(Date:9/22/2014)... have generated a new star-shaped molecule made up of interlocking ... created. , Known as a ,Star of David, ... a quarter of a century and the team,s findings are ... Consisting of two molecular triangles, entwined about each other three ... each triangle is 114 atoms in length around the ...
(Date:9/22/2014)... This is a professional and in-depth ... industry in Global and China. The report provides ... and industry chain structure. Global market analysis and Chinese ... history, developments, trends and competitive landscape of the market. ... also offered. , The report also focuses on development ...
(Date:9/22/2014)... California (PRWEB) September 22, 2014 ... primal desire to stay young has groomed and ... dollar industry worldwide. Growing emphasis on appearance maintenance ... Toxin is a neurotoxic protein obtained from the ... acetylcholine, resulting in muscle relaxation. With cosmetic indications ...
Breaking Biology Technology:Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 2Global Biotechnology Reagents Market 2014-2018: Key Vendors are Agilent, BD Biosciences, Bio-Rad, F. Hoffmann-La Roche, Sigma-Aldrich and Thermo Fisher 3m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 2m-Phenylenediamine Industry: mPDA Global & China Trend Analysis Now Available at ReportsnReports.com 3Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 2Strong Demand for Non-Invasive Cosmetic Procedures Drives the Global Botulinum Toxin Market, According to New Report by Global Industry Analysts, Inc. 3
... Mass., March 19 MacroChem,Corporation (OTC Bulletin Board: ... to the position of Chief Financial Officer, effective,immediately. ... and Vice,President, Corporate Development since joining the Company ... CFO of Bioenvision, Inc. prior to its,successful merger ...
... Years In 2008 And, Beyond, According To The Latest Research Released By ... ... the economy slides into,recession, IBISWorld today announced its list of industries with ... of the top 10 industries which IBISWorld predicts to do,well in 2008 ...
... of Standards and Technology (NIST) have set the stage ... today built from semiconductor compounds and future generations of ... upcoming paper in the Journal of the American Chemical ... of organic molecules can be assembled on the same ...
Cached Biology Technology:MacroChem Appoints David P. Luci as New CFO 2MacroChem Appoints David P. Luci as New CFO 3The Recession List - Top 10 Industries to Fly and Flop in 2008 2The Recession List - Top 10 Industries to Fly and Flop in 2008 3The Recession List - Top 10 Industries to Fly and Flop in 2008 4The Recession List - Top 10 Industries to Fly and Flop in 2008 5The Recession List - Top 10 Industries to Fly and Flop in 2008 6NIST team proves bridge from conventional to molecular electronics possible 2
(Date:9/23/2014)... -- Newest Market IPO,s and exchange ... significant investor attention with news concerning shareholder updates and new ... NXT-ID, Inc. (NASDAQ: NXTD ), Alibaba Group Holding ... MBLY ), GoPro, Inc. (NASDAQ: GPRO ) ... (NASDAQ: NXTD ) recently completed an essential round ...
(Date:9/22/2014)... ATLANTA September 23, 2014 A new American ... Supplemental Nutrition Assistance Program (SNAP), previously known as ... scores compared with income eligible non-participants. The authors ... programs aimed at enhancing the dietary quality of ... assist low-income individuals and households with the resources ...
(Date:9/22/2014)... genetic sequencing technologies continue to evolve rapidly, becoming part ... establish appropriate policies and regulatory frameworks to address potential ... policy issue of the Journal of Law, Medicine ... experts with the Center for Medical Ethics and Health ... the tools to jumpstart this process. , Experts ...
Breaking Biology News(10 mins):Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 2Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 3Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 4Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 5Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 6Latest Blockbuster IPOs and Up Listings for Global Tech Stocks Attracting Major Attention as Traders Focus on Key Economic Data Due this Week 7Federal food program puts food on the table, but dietary quality could be improved 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 2Experts provide much-needed policy analysis for clinical integration of next generation sequencing 3
... The MRSA 'superbug' evades many of the measures introduced ... organism found almost everywhere in hospital wards, according to ... Scientists from the University of Bath have shown that ... called Acanthamoeba polyphaga, which is ubiquitous in the environment ...
... cancers actually share something in common ?a molecular "signature" made ... that target key cancer genes and promote malignant growth. ... emerging class of gene regulators and may also pave the ... The study appears online in the Proceedings of the National ...
... discovered that some type of protective system goes into ... is deficient. This discovery indicates a hidden safety net ... the immune system such as AIDS. The Mayo Clinic-led ... and is reported in the early online edition of ...
Cached Biology News:MRSA use amoeba to spread, new research shows 2Common molecular 'signature' identified in solid tumors 2Common molecular 'signature' identified in solid tumors 3Infant transplant patients resist infections that kill adult AIDS patients 2Infant transplant patients resist infections that kill adult AIDS patients 3
... is a new product number, created ... If showing no availability yet, please ... (Z71,487-9) or contact customer service for ... 100 mm, No. of sidearm 4 ...
... 15(S)-15-methyl PGF2α is a metabolically ... is a potent uterine stimulant ... administered intramuscularly to induce labor. ... serum progesterone concentrations when given ...
TGase3 (S-20)...
Amodiaquine...
Biology Products: